A Single Center Pilot Trial of Rituximab in the Treatment of Fibrillary Glomerulonephritis
Phase of Trial: Phase II
Latest Information Update: 14 Feb 2019
Price : $35 *
At a glance
- Drugs Rituximab (Primary)
- Indications Glomerulonephritis
- Focus Therapeutic Use
- 16 Oct 2017 Status changed from active, no longer recruiting to completed.
- 27 Apr 2016 Planned number of patients changed from 10 to 11.
- 27 Apr 2016 Planned End Date changed from 1 Oct 2016 to 1 Apr 2017.